Shenyang Xingqi PharmaceuticalLtd Past Earnings Performance
Past criteria checks 6/6
Shenyang Xingqi PharmaceuticalLtd has been growing earnings at an average annual rate of 32.5%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 23.9% per year. Shenyang Xingqi PharmaceuticalLtd's return on equity is 21.4%, and it has net margins of 19.3%.
Key information
32.5%
Earnings growth rate
30.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 23.9% |
| Return on equity | 21.4% |
| Net Margin | 19.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Shenyang Xingqi PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,802 | 348 | 806 | 185 |
| 30 Jun 24 | 1,674 | 322 | 759 | 168 |
| 31 Mar 24 | 1,531 | 255 | 715 | 177 |
| 31 Dec 23 | 1,468 | 240 | 693 | 167 |
| 30 Sep 23 | 1,350 | 191 | 657 | 177 |
| 30 Jun 23 | 1,335 | 179 | 666 | 173 |
| 31 Mar 23 | 1,234 | 157 | 631 | 152 |
| 01 Jan 23 | 1,250 | 212 | 596 | 146 |
| 30 Sep 22 | 1,262 | 241 | 586 | 117 |
| 30 Jun 22 | 1,166 | 235 | 527 | 101 |
| 31 Mar 22 | 1,123 | 236 | 494 | 91 |
| 01 Jan 22 | 1,028 | 195 | 456 | 88 |
| 30 Sep 21 | 990 | 190 | 441 | 77 |
| 30 Jun 21 | 914 | 153 | 415 | 70 |
| 31 Mar 21 | 813 | 132 | 363 | 70 |
| 31 Dec 20 | 689 | 88 | 322 | 63 |
| 30 Sep 20 | 602 | 61 | 289 | 61 |
| 30 Jun 20 | 528 | 45 | 261 | 61 |
| 31 Mar 20 | 514 | 24 | 278 | 57 |
| 31 Dec 19 | 542 | 36 | 294 | 54 |
| 30 Sep 19 | 504 | 29 | 283 | 54 |
| 30 Jun 19 | 480 | 21 | 277 | 46 |
| 31 Mar 19 | 453 | 17 | 264 | 42 |
| 31 Dec 18 | 431 | 14 | 247 | 41 |
| 30 Sep 18 | 416 | 11 | 238 | 36 |
| 30 Jun 18 | 379 | 9 | 196 | 54 |
| 31 Mar 18 | 362 | 28 | 175 | 43 |
| 31 Dec 17 | 360 | 39 | 177 | 34 |
| 30 Sep 17 | 361 | 51 | 174 | 26 |
| 30 Jun 17 | 356 | 51 | 205 | 0 |
| 31 Mar 17 | 347 | 55 | 198 | 0 |
| 31 Dec 16 | 339 | 54 | 187 | 0 |
| 31 Dec 15 | 287 | 22 | 158 | 0 |
| 31 Dec 14 | 255 | 31 | 153 | 0 |
| 31 Dec 13 | 219 | 46 | 133 | 0 |
Quality Earnings: 300573 has high quality earnings.
Growing Profit Margin: 300573's current net profit margins (19.3%) are higher than last year (14.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300573's earnings have grown significantly by 32.5% per year over the past 5 years.
Accelerating Growth: 300573's earnings growth over the past year (82.3%) exceeds its 5-year average (32.5% per year).
Earnings vs Industry: 300573 earnings growth over the past year (82.3%) exceeded the Pharmaceuticals industry -2.5%.
Return on Equity
High ROE: 300573's Return on Equity (21.4%) is considered high.